{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Response rate after completion of first cycle. Measured as the proportion of subjects who have a partial response (PR) or complete response (CR), represented as the overall response rate (ORR). SWOG/IBMTR (Southwest Oncology Group/International Blood and Marrow Transplant Research) criteria utilized to determine multiple myeloma response rates.","groups":[{"description":"Doxil, Thalidomide, Dexamethasone\n\nDoxil: Doxil 40 mg/m2 IV day 1\n\nThalidomide: 50-100 mg day 1-28\n\nDexamethasone: Dexamethasone 40 mg day 1-4 and 15-18","id":"OG000","title":"Arm 1"}],"paramType":"NUMBER","populationDescription":"Five subjects did not complete first cycle.","reportingStatus":"POSTED","timeFrame":"At End of Cycle 1, 28 Days","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}